Collectively, our findings provide evidence for the pre-clinical efficacy of the SHP-1 agonist SC-43 in attenuating macrophage accumulation within the lung, mitigating pulmonary fibrosis, and enhancing survival. This evidence concerns the gene PTPN6 and pulmonary fibrosis.